Skip to content

Avantor AVTR Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Minerals Technologies logo
Minerals TechnologiesMTX

Other financials

Income statement

See full
Revenue$1.7B+0.5%
Gross profit$537.0M-3.1%
Operating income$121.8M-5.4%
Net income$38.1M-41.1%
EPS (diluted)$0.06-33.3%

Balance sheet

See full
Cash & equivalents$309.7M-31.5%
Total debt$3.7B-12.8%
Total equity$5.6B-10.4%
Total assets$11.6B-9.2%

Cash flow

See full
Operating cash flow$178.2M+15.4%
CapEx$37.6M+27.0%
Free cash flow$140.6M+12.7%

Valuation

See full
Market cap$8.48B-11.2%
Enterprise value$11.87B-11.0%
P/S1.3×-0.1×

Profitability

See full
Gross margin31.8%-1.4pp
Operating margin4%-5.2pp
Net margin-9.6%-19.9pp
FCF margin6.9%-1.4pp

Returns & leverage

See full
Return on equity-10.6%-22.3pp
Debt / equity0.7×0.0×
Current ratio1.8×+0.8×

Where this comes from

Reported directly by Avantor in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Avantor’s 10-Q, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avantor's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avantor's other noncash income (expense)?
Avantor (AVTR) reported other noncash income (expense) of -$1.7M in Q2 2026.
How has Avantor's other noncash income (expense) changed year-over-year?
Avantor's other noncash income (expense) decreased by 325.0% year-over-year, from -$400K to -$1.7M.
What is the long-term trend for Avantor's other noncash income (expense)?
Over 2 years (2022 to 2025), Avantor's other noncash income (expense) has grown at a -56.9% compound annual growth rate (CAGR), from $7M to $1.3M.